Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

A Randomized 3-Arm Phase II Study Comparing 1. Bendamustine, Rituximab and High Dose Cytarabine BR/CR 2. Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib BR/CR-A, and 3.Bendamustine, Rituximab and Acalabrutinib BR-A in Patients ? 70 years old with Untreated Mantle Cell Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04115631

Study #:
STUDY00144893

Start Date:
Feb 27, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04115631

View Complete Trial Details & Eligibility at ClinicalTrials.gov